tirzepatide cardiovascular outcomes trial

tirzepatide cardiovascular outcomes trial Cardiorenal With Compared With Dulaglutide in Patients With Diabetes and Disease A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Compared with the GLP-1 agonist dulaglutide, the dual tirzepatide cardiovascular outcomes study Effects

Name: tirzepatide cardiovascular outcomes trial Cardiorenal With Compared With Dulaglutide in Patients With Diabetes and Disease A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Compared with the GLP-1 agonist dulaglutide, the dual tirzepatide cardiovascular outcomes study Effects
Brand: actil.am
SKU: 57118079468
Price: 23.81 USD
Availability: InStock
Rating: 4.3474 (28 reviews)

SKU: 57118079468

4.3

USD23.81 USD63.81

Pay in 4 interest-free payments of $5.95 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 29 - Sep 3

Description

GLP-1s were associated with a significant risk reduction for 10 different cancers when used to treat Type 2 diabetes compared to insulin, according to research published in JAMA Oncology